2023
Histone deacetylase inhibitors mitigate antipsychotic risperidone-induced motor side effects in aged mice and in a mouse model of Alzheimer’s disease
Rodriguez G, Fisher D, McClarty B, Montalvo-Ortiz J, Cui Q, Chan C, Dong H. Histone deacetylase inhibitors mitigate antipsychotic risperidone-induced motor side effects in aged mice and in a mouse model of Alzheimer’s disease. Frontiers In Psychiatry 2023, 13: 1020831. PMID: 36684015, PMCID: PMC9852991, DOI: 10.3389/fpsyt.2022.1020831.Peer-Reviewed Original ResearchMotor side effectsSevere neuropsychiatric symptomsAged miceSide effectsHDAC inhibitorsNeuropsychiatric symptomsDementia patientsHistone deacetylase inhibitor valproic acidAtypical antipsychotic risperidoneTypical antipsychotic haloperidolAntipsychotic drug targetsGreater side effectsInhibitor valproic acidHistone deacetylase inhibitorsAge-related sensitivityEpigenetic alterationsAtypical antipsychoticsD2R expressionAntipsychotic haloperidolLabel useAntipsychotic risperidoneAntipsychotic drugsMouse modelValproic acidClinical practice
2022
The role of alcohol intake in the pharmacogenetics of treatment with clozapine
Monroy-Jaramillo N, Martínez-Magaña JJ, Pérez-Aldana BE, Ortega-Vázquez A, Montalvo-Ortiz J, López-López M. The role of alcohol intake in the pharmacogenetics of treatment with clozapine. Pharmacogenomics 2022, 23: 371-392. PMID: 35311547, DOI: 10.2217/pgs-2022-0006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdverse reactionsAlcohol intakeConcomitant useSevere adverse reactionsGood therapeutic effectPrecision medicine approachRefractory psychosisAtypical antipsychoticsInterindividual responseTherapeutic effectClozapineMedicine approachPharmacogenetic studiesSignificant riskIntakePatientsGenetic variantsPharmacogeneticsAntipsychoticsPsychosisCYP1A2Receptors